Brokerages Set Omeros Co. (NASDAQ:OMER) Target Price at $22.50

Omeros Co. (NASDAQ:OMER) has earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $22.50.

OMER has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Friday. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Rodman & Renshaw began coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in OMER. BNP Paribas Financial Markets grew its position in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. MML Investors Services LLC grew its position in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. SPC Financial Inc. acquired a new position in shares of Omeros during the 3rd quarter worth approximately $77,000. SG Americas Securities LLC acquired a new position in shares of Omeros during the 3rd quarter worth approximately $80,000. Finally, AQR Capital Management LLC acquired a new position in shares of Omeros during the 2nd quarter worth approximately $105,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Performance

NASDAQ:OMER opened at $9.33 on Friday. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The firm has a market cap of $540.67 million, a P/E ratio of -4.04 and a beta of 2.01. The firm’s fifty day moving average is $9.35 and its 200-day moving average is $6.03.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.